Watermark
  Back to Search Results

BGB-A317-303

Completed

Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

BGB-A317-303

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT03358875

EudraCT Number Info icon SVG graphic used for tooltips or additional information.

2018-000245-39

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20171112

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan